Manufacturing MES

Cross-Site Production Visibility & Scheduling

Large pharmaceutical companies operate 10–50+ sites across multiple countries, each with different regulatory frameworks. Without a unified system, the COO sees quarterly PowerPoint aggregations instead of real-time data. Leucine MES changes this: one platform across all sites, real-time production dashboards, cross-site scheduling, and AI that detects deviation patterns across the network. At Cipla, 30 manufacturing facilities with 2,500+ concurrent users run on a single Leucine MES instance — recognised by the World Economic Forum as a Global Lighthouse.

Key Highlights

01 30 manufacturing sites on one platform (Cipla, WEF Global Lighthouse)
02 2,500+ concurrent users across all facilities
03 Multi-regulatory: FDA, EMA, MHRA, CDSCO on a single MES instance
04 10+ facilities digitised globally (Piramal) across 3 regulatory jurisdictions

Regulatory Context

What FDA Inspectors Cite

21 CFR 211.188 Format Inconsistency
1 / 6

Same product, different documentation standards across sites

FDA inspectors found that the same product manufactured at two sites produced batch records with different fields, terminology, and data capture methods. No enterprise-wide standard existed, making cross-site quality comparison impossible.

Lupin Limited · 2024-06-20
21 CFR 211.100 Tech Transfer Gap
2 / 6

Technology transfer documentation incomplete — site-specific adaptations undocumented

When a product was transferred from development to commercial manufacturing, critical process parameter ranges and equipment-specific adaptations were not formally documented. The receiving site operated with incomplete MBRs.

Aurobindo Pharma Limited · 2024-11-08
21 CFR 211.180(e) Cross-Site Trending
3 / 6

Deviation trending not performed across sites — recurring issues invisible

The same deviation type appeared at three manufacturing sites over 18 months, but each site investigated independently. The systemic root cause was identified only after FDA flagged the pattern during a multi-site inspection.

Dr. Reddy’s Laboratories Limited · 2025-07-18
21 CFR 211.180(e) Reporting Lag
4 / 6

Quality metrics reported manually — months of delay between production and enterprise visibility

Site-level quality metrics were compiled manually in spreadsheets and reported to corporate quality quarterly. By the time leadership saw the data, the production conditions that caused quality issues had changed.

Glenmark Pharmaceuticals · 2023-07-12
21 CFR 211.68 Equipment Visibility
5 / 6

Equipment qualification status unknown across sites — no centralised view

During a multi-site inspection, FDA requested equipment qualification status across three facilities. The firm could not provide a consolidated view — each site maintained separate records in different formats. Compiling the response took weeks.

Hetero Labs Limited · 2024-04-22
21 CFR 211.192 CAPA Propagation
6 / 6

Corrective actions at one site not shared with other sites manufacturing the same product

A CAPA implemented at one facility after a yield-related deviation was not communicated to two other facilities manufacturing the same product. Both facilities experienced the same issue in subsequent months.

Glenmark Pharmaceuticals Limited · 2025-02-10

The Problem

Why Multi-Site Pharma Operates Blind

Challenge 1 1 / 6

Every Site Is a Data Island

  • 10–50+ sites with different systems, formats, and data capture methods
  • Enterprise-wide quality dashboards are impossible without standardised digital data
  • The same product at two sites produces records with different fields and terminology
Challenge 2 2 / 6

Scheduling Is Site-by-Site

  • If Site A has excess capacity and Site B has a backlog, nobody knows in real time
  • 10–20% of network capacity sits underutilised because of siloed scheduling
  • Demand shifts require manual phone calls and email chains to rebalance
Challenge 3 3 / 6

Technology Transfer Takes Months

  • MBR re-entry takes weeks per product — error-prone and labour-intensive
  • Equipment-specific adaptations often undocumented, leading to deviations
  • Capacity expansion bottlenecked by transfer timelines, not facility readiness
Challenge 4 4 / 6

Cross-Site Quality Comparison Is Manual

  • Quarterly PowerPoint reports compiled from spreadsheets are the enterprise "dashboard"
  • By the time leadership sees the data, production conditions have changed
  • Root causes for yield differences between sites are invisible without structured data
Challenge 5 5 / 6

Deviation Patterns Invisible Across Sites

  • Same deviation at three sites over 18 months caught only by an FDA multi-site inspection
  • CAPAs at one site not propagated to other sites manufacturing the same product
  • Systemic root causes persist because each site sees only its own data
Challenge 6 6 / 6

Legacy MES Takes 12–18 Months Per Site

  • Traditional MES implementations typically take 12–18 months per site
  • A 10-site rollout becomes a 5–7 year programme with traditional vendors
  • The ROI case collapses when deployment timelines extend beyond 2–3 years

Multi-Site Operations in Leucine MES

1

Single Platform, Multi-Site Architecture

One MES instance deployed across all sites. Not separate installations stitched together — a true multi-tenant architecture where each site has its own configuration but data flows to a unified enterprise layer.

Site Configuration Equipment Mapping Regulatory Routing User Management
2

Global Production Dashboard

Real-time view of every site's production status: batches in progress, equipment status, line utilisation. The COO sees the entire network on one screen — not individual site reports aggregated weeks later.

Real-Time Aggregation Site-Level Drill-Down KPI Computation Alert Generation
3

Cross-Site Scheduling & Capacity Balancing

When Site A has capacity and Site B has a backlog, the system identifies the imbalance. Scheduling considers site capabilities, regulatory status, and product-site qualifications to recommend optimal allocation.

Capacity Balancing Product-Site Matching Constraint Optimisation Rebalancing Alerts
4

Technology Transfer Automation

When a product is validated at one site, the digital MBR can be replicated to another with site-specific equipment mappings and process parameter adaptations — eliminating weeks of manual re-entry.

MBR Replication Equipment Adaptation Parameter Mapping Validation Checklist
5

Cross-Site Deviation & CAPA Intelligence

Cortex AI identifies recurring deviation patterns across sites. If Site A and Site C both have yield drops on the same product, the system connects the dots. CAPAs at one site are flagged for propagation to all relevant facilities.

Cross-Site Pattern Detection Deviation Correlation CAPA Propagation Systemic Root Cause

The Solution

How Leucine Solves This

Addressing both the operational blind spots that cost millions in underutilised capacity and the compliance gaps FDA finds during multi-site inspections.

MES Multi-Site Platform

One MES Across All Sites — Real-Time, Not Quarterly

A single MES instance spanning all manufacturing sites with site-specific configuration, equipment mapping, and regulatory compliance. Global production dashboard replaces quarterly PowerPoint reports.

  • Multi-tenant architecture — one platform, site-specific configurations
  • Global production dashboard with real-time batch and equipment status
  • Cross-site scheduling with capacity balancing and product-site qualification
LeucineOS Cross-Site Intelligence

Network-Level Quality Intelligence

LeucineOS analyses structured data from all sites to surface cross-site yield comparisons, deviation patterns, and quality trends invisible to individual site operations.

  • Cross-site yield and OEE comparison — same metrics, same definitions
  • Deviation correlation across sites, products, and equipment types
  • CAPA propagation tracking — corrections reach all relevant facilities
MES Technology Transfer

Move Products Between Sites in Weeks, Not Months

Digital MBR replication with site-specific equipment and parameter adaptations eliminates manual re-entry and reduces transfer-related deviations.

  • Digital MBR replication from source site to target site
  • Automated equipment mapping and parameter adaptation
  • Transfer validation checklist with approval workflow
FDA Tracker

Multi-Site Inspection Intelligence

Track FDA enforcement patterns across your facility network. Know what FDA is citing at similar manufacturers and how your compliance posture compares.

  • Multi-site inspection history tracking with citation pattern analysis
  • Peer benchmarking against industry enforcement trends
  • Early warning for enforcement areas affecting multi-site manufacturers

Results

Measurable Impact

Real results from pharmaceutical manufacturers running Leucine MES across their global manufacturing networks.

30+
Facilities on One Platform
Manufacturing sites running Leucine MES at Cipla — WEF Global Lighthouse designation
2,500+
Concurrent Users
Operators, supervisors, and QA staff across all Cipla facilities on a single MES
3
Regulatory Jurisdictions
FDA, MHRA, and EMA compliance harmonised on one platform across 10+ Piramal sites
95%
Batch Review Time
Reduction — from 20 days to 1 day at Valent BioSciences

Next Step

Get Started

Stop managing your manufacturing network through quarterly PowerPoints. Leucine MES gives you real-time visibility across every site — deployed in weeks, not years.

Get Started
Exit